Search

Nowadays, it is generally accepted that rising concerns over environmental challenges and deviant climate changes are caused by the profuse utilization of conventional fossil fuels. The use of renewable energy systems, such as wind and solar power, is greatly considered to be one of the most significant replacements to enable more fast societal development and sustainable economic growth. For this purpose, sustainable and promising electrochemical energy storage technologies (ESTs), such as batteries and supercapacitors, can contribute a significantly vital role. Lithium-ion batteries (LIBs) are the only commercially available batteries that are up to date, and their development was acknowledged through the 2019 Nobel Prize in chemistry. To further boost the power and energy densities of LIBs, silicon nanomaterial-based anodes have been widely investigated owing to their low operation potential, high storage capacity, high abundance, and environmentally benign nature. However, the formation of unstable solid–electrolyte interphase (SEI) layers and the large volumetric changes during the discharge/charge processes are the key challenges for the commercialization of these anode materials. Here, the most recent development in the applications of silicon-based nanomaterials in LIBs and supercapacitors is summarized. A brief account on the electrochemical performance of silicon-based hybrid nanomaterials constructed by various strategies is systematically reviewed.

Alzheimer’s disease (AD), a neurological disorder, is as a complex chronic disease of brain cell death that usher to cognitive decline and loss of memory. Its prevalence differs according to risk factors associated with it and necropsy performs vital role in its definite diagnosis. The stages of AD vary from preclinical to severe that proceeds to death of patient with no availability of treatment. Biomarker may be a biochemical change that can be recognized by different emerging technologies such as proteomics and metabolomics. Plasma biomarkers, 5-protein classifiers, are readily being used for the diagnosis of AD and can also predict its progression with a great accuracy, specificity, and sensitivity. In this review, upregulation or downregulation of few plasma proteins in patients with AD has also been discussed, when juxtaposed with control, and thus serves as potent biomarker in the diagnosis of AD.